ISCO (International Stem Cell) EPS (Basic): $-0.06 (TTM As of Mar. 2026)

What is International Stem Cell EPS (Basic)?

International Stem Cell ISCO +4.76% 28 EPS (Basic) is $-0.06 as of Mar. 2026. GuruFocus rates ISCO with a GF Score™ of 28/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 4 warning signs investors should review.

International Stem Cell's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.06.

International Stem Cell's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.06.

International Stem Cell's EPS without NRI for the three months ended in Mar. 2026 was $-0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.06.

During the past 3 years, the average EPS without NRI Growth Rate was -7.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 36.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 37.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, International Stem Cell's highest 3-Year average EPS without NRI Growth Rate was 62.80% per year. The lowest was -46.20% per year. And the median was 27.10% per year.

International Stem Cell (OTCPK:ISCO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

International Stem Cell EPS (Basic) Related Terms

International Stem Cell EPS (Basic) Historical Data

* Premium members only.

The historical data trend for International Stem Cell's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

International Stem Cell EPS (Basic) Chart

International Stem Cell Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

-0.11

-0.04

-0.02

-0.03

-0.05

International Stem Cell Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															-0.03	0.01	0.00	-0.04	-0.03

28GF Score

International Stem Cell Corp ISCO

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

International Stem Cell EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

International Stem Cell's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.418	-	0)	/	8.004
	=	-0.05

International Stem Cell's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.22	-	0)	/	8.004
	=	-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of $-0.06 mean?

International Stem Cell (ISCO) has a EPS (Basic) of $-0.06 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on International Stem Cell and its competitors.

Is International Stem Cell's EPS (Basic) too high?

International Stem Cell's current EPS (Basic) is $-0.06. Overall, International Stem Cell has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does International Stem Cell's EPS (Basic) compare to ONCO and VRAX?

International Stem Cell's EPS (Basic) of $-0.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on International Stem Cell and its competitors. International Stem Cell's current EPS (Basic) is $-0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is International Stem Cell stock overvalued right now?

Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.18 — trading 37% above its estimated fair value. The current EPS (Basic) is $-0.06. International Stem Cell's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For International Stem Cell (ISCO), the current EPS (Basic) is $-0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is International Stem Cell (ISCO) Overvalued in 2026?

Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued. The current stock price of $0.18 is trading 37% above its estimated GF Value™ of $0.13. GuruFocus considers International Stem Cell to be Significantly Overvalued.

Key valuation signals for ISCO:

EPS (Basic): $-0.06
GF Value™: $0.13 vs. price of $0.18 (37% above fair value)
GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

International Stem Cell Business Description

Industry Healthcare Biotechnology

Comparable Companies ONCO VRAX LYRA ABPO BPTH ADAPY ZVSA CLSDQ BZYR ATXI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 9745 Businesspark Avenue, San Diego, CA, USA, 92131

Website https://www.internationalstemcell.com

International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.

28GF Score

Get the complete analysis for ISCO

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18

Price

$0.13

GF Value

View ISCO Analysis

See EPS (Basic) data for all stocks →